Clinical Trials
2 trialsNCT03038672 2026-05-12
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03309878 2023-09-21
Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
National Cancer Institute (NCI)
Phase 1/2 Completed